Cellect Biotechnology Ltd.: Significant recently reported findings open the ApoGraft™ platform to also be used in the fat-derived stem cell segment; price target raised to $16.9

• jaimeuss_admin
• 30 בAugust 2018
• Research
• 0 Comments

Continue Reading

Safe-T: The company continues to successfully implement its growth strategy. Raised capital, launched a new web site and marketing activities, received first orders for its newly announced solution and is gearing up for dual-trading. Price target remains at NIS 9.38.

• jaimeuss_admin
• 30 בAugust 2018
• Research
• 0 Comments

Continue Reading

BioLineRx Ltd.: Company is on track with its execution of multiple clinical development programs for the Company’s lead project – BL-8040; Sufficient funds to support this development; Stock price target raised to NIS 5.15

• jaimeuss_admin
• 30 בAugust 2018
• Research
• 0 Comments

Continue Reading